Lupus Low Disease Activity State (LLDAS) Achievement with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE

被引：0

作者：

Morand, Eric ^{[1
]}

Hobar, Coburn ^{[2
]}

Pomponi, Samantha ^{[3
]}

Koti, Ravi ^{[4
]}

Wegman, Thomas ^{[5
]}

van Vollenhoven, Ronald ^{[6
]}

机构：

[1] Monash Univ, Ctr Inflammatory Dis, Melbourne, Vic, Australia

[2] Bristol Myers Squibb, Bradenton, FL USA

[3] Bristol Myers Squibb, Princeton, NJ USA

[4] Syneos Hlth, Morrisville, NC USA

[5] Bristol Myers Squibb, Beaver Falls, PA USA

[6] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1501

引用

页码：2961 / 2963

页数：3

共 2 条

[1] Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial [J].

Morand, Eric ;

Pike, Marilyn ;

Merrill, Joan T. ;

van Vollenhoven, Ronald ;

Werth, Victoria P. ;

Hobar, Coburn ;

Delev, Nikolay ;

Shah, Vaishali ;

Sharkey, Brian ;

Wegman, Thomas ;

Catlett, Ian ;

Banerjee, Subhashis ;

Singhal, Shalabh .

ARTHRITIS & RHEUMATOLOGY, 2023, 75 (02) :242-252

[2] Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort [J].

Petri, Michelle ;

Magder, Laurence S. .

ARTHRITIS & RHEUMATOLOGY, 2018, 70 (11) :1790-1795

← 1 →